ACEPODIA
"ACEPODIA" is a word mark owned by Acepodia Biotechnologies Ltd., filed at the USPTO on June 15, 2023. It is registered and covers class 5 (Pharmaceuticals).
- Status
- Registered
- Since February 10, 2026
- Filed
- June 15, 2023
- Registered
- February 10, 2026
- Expires
- Not recorded
- Application no.
- 98044259
- Registration no.
- 8137873
- Office
- USPTO
- United States Patent and Trademark Office
- Mark type
- Word mark
- 1 class
Who owns ACEPODIA
The owner and representative on file with the office.
Owner
Acepodia Biotechnologies Ltd.
Taipei City, Taiwan
Representative
Evan R. Witt
Kirton McConkie
What the mark covers
The products and services ACEPODIA is filed for, grouped by Nice class.
Biological preparations for use in cell cultures for medical or therapeutic purposes; Biological tissue cultures for medical purposes; Medicinal preparations for the treatment and prevention of cancer, tumors, autoimmune disease, neuronal disease, hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases for human purposes; Drugs, namely, pharmaceuticals for the treatment and prevention of cancer, tumors, autoimmune disease, neuronal disease, hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases for medical purposes; Pharmaceutical preparations for the treatment and prevention of cancer, tumors, autoimmune disease, neuronal disease, hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases; Cells for clinical, medical, veterinary, or therapeutic purposes or use; Cell-derived preparations, namely, natural killer cell, gamma delta T cell, or other immune cell-derived preparations, for clinical, medical, veterinary, or therapeutic purposes; Therapeutic products derived from cells or cell-derived preparations, namely, natural killer cells, gamma delta T cell, and other immune cell, for clinical, medical, veterinary, or therapeutic purposes; Kits comprised of cells and reagents and also containing related instructions for clinical, medicinal, veterinary, or therapeutic purposes or use; Kits comprised of cell-derived preparations, namely, natural killer cell, gamma delta T cell, and other immune cell-derived preparations and reagents and also containing related instructions, for clinical, medicinal, veterinary, or therapeutic purposes or use; Pharmaceutical preparations, pharmaceutical products, therapeutic agents, and pharmaceuticals for targeting tissues based on select tissue markers and ligands, or for the purpose of binding ligands using engineered proteins and receptors; Pharmaceuticals, namely, pharmaceutical preparations, pharmaceutical products, therapeutic agents, and pharmaceuticals for use in the prevention and treatment of cancer, tumors, hematologic disease, solid cancers, hyperproliferative disease, autoimmune disease, neuronal diseases, hematopoietic cell-related diseases, metabolic syndrome, infectious diseases, immune disease or disorder, and inflammation and inflammatory diseases and in cellular transplants; Biotechnology and pharmaceutical products, namely, therapeutic cells, therapeutic peptide, therapeutic proteins, and therapeutic nucleic acids for human use for the treatment and prevention of cancer, tumors, autoimmune disease, a neuronal disease, a hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases; Pharmaceutical preparations or pharmaceutical products, namely, cell media for use in activating t-cells for use in adoptive t-cell therapy for the treatment of hematological and solid cancers; Pharmaceutical preparations, biological preparations, and therapeutic agents to modulate cell function or cell fate; Biological preparations and therapeutic agents used for medical cell therapy, adoptive immunotherapy, or other immunotherapy; Therapeutic cell preparation based on NK cells (natural killer cells), gamma delta T cell, other immune cell, or other cell for the treatment of cancer, tumors, neuronal diseases, hematopoietic cell-related diseases, metabolic syndrome, infectious diseases, auto-immune diseases, and inflammatory and immune disorders; Bio-engineered component for a therapeutic material, namely, cell lines based on NK cells (natural killer cells), gamma delta T cell, or other immune cell used for medical or clinical use used for immunotherapy
What has happened so far
Steps recorded by the USPTO, newest first.
- Notice of registration confirmation emailed
- Registered-principal register
- Notice of acceptance of statement of use e-mailed
- Allowed principal register - sou accepted
- Statement of use processing complete
- Case assigned to intent to use paralegal
- Use amendment filed
- Teas statement of use received
- Notice of approval of extension request e-mailed
- Sou extension 1 granted
10 earlier steps on the official record.
About ACEPODIA
Who owns the trademark "ACEPODIA"?
The USPTO trademark "ACEPODIA" (application 98044259) is owned by Acepodia Biotechnologies Ltd.
What is the status of "ACEPODIA"?
Its status at the USPTO is: registered.
When was "ACEPODIA" registered?
It was registered on February 10, 2026.
Get this data via the API
Everything on this page comes from the Signa API. Pull ACEPODIA and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019d2bd2-627d-74fa-b0b7-73dc40ed141e
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019d2bd2-627d-74fa-b0b7-73dc40ed141e",
"object": "trademark",
"mark_text": "ACEPODIA",
"status": {
"primary": "active",
"stage": "registered"
},
"office_code": "US",
"application_number": "98044259",
"filing_date": "2023-06-15",
"nice_classes": [
5
],
"owners": [
{
"name": "Acepodia Biotechnologies Ltd.",
"entity_id": null
}
]
}